- Home
- EVM vs ELDN Comparison
EVM vs ELDN Comparison
Compare EVM & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- ELDN
- Stock Information
- Founded
- EVM 2002
- ELDN 2004
- Country
- EVM United States
- ELDN United States
- Employees
- EVM N/A
- ELDN N/A
- Industry
- EVM Finance/Investors Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- ELDN Health Care
- Exchange
- EVM Nasdaq
- ELDN Nasdaq
- Market Cap
- EVM 213.2M
- ELDN 202.4M
- IPO Year
- EVM N/A
- ELDN N/A
- Fundamental
- Price
- EVM $9.00
- ELDN $2.55
- Analyst Decision
- EVM
- ELDN Strong Buy
- Analyst Count
- EVM 0
- ELDN 2
- Target Price
- EVM N/A
- ELDN $12.50
- AVG Volume (30 Days)
- EVM 55.8K
- ELDN 895.7K
- Earning Date
- EVM 01-01-0001
- ELDN 08-14-2025
- Dividend Yield
- EVM 4.01%
- ELDN N/A
- EPS Growth
- EVM N/A
- ELDN N/A
- EPS
- EVM 0.20
- ELDN 0.21
- Revenue
- EVM N/A
- ELDN N/A
- Revenue This Year
- EVM N/A
- ELDN N/A
- Revenue Next Year
- EVM N/A
- ELDN N/A
- P/E Ratio
- EVM $47.61
- ELDN $12.10
- Revenue Growth
- EVM N/A
- ELDN N/A
- 52 Week Low
- EVM $7.67
- ELDN $2.38
- 52 Week High
- EVM $9.59
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- EVM 56.97
- ELDN 36.69
- Support Level
- EVM $8.87
- ELDN $2.54
- Resistance Level
- EVM $9.14
- ELDN $2.70
- Average True Range (ATR)
- EVM 0.08
- ELDN 0.11
- MACD
- EVM 0.01
- ELDN 0.01
- Stochastic Oscillator
- EVM 57.14
- ELDN 20.00
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.